Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials
- 20 February 2014
- journal article
- review article
- Published by Informa UK Limited in Immunopharmacology and Immunotoxicology
- Vol. 36 (2), 96-104
- https://doi.org/10.3109/08923973.2014.890626
Abstract
The costimulatory molecule CD40 is a member of the tumor necrosis factor (TNF) receptor superfamily and is expressed on various antigen presenting cells (APCs) as well as some tumor cells. The binding to the natural ligand CD40L, which is expressed on T helper cells, leads to APC activation and thus enhancement of immune responses. Treatment with anti-CD40 monoclonal antibodies has been exploited in several cancer immunotherapy studies in mice and led to the development of anti-CD40 antibodies for clinical use. Here, Dacetuzumab and Lucatumumab are in the most advanced stage and are being tested as treatment for malignancies such as chronic lymphatic leukemia (CLL), Multiple Myeloma (MM), and non-Hodgkin's lymphoma (NHL). The promising results from these early clinical trials have encouraged clinical drug development in order to investigate the effect of CD40 mAbs in combination with other cancer immunotherapies, in particular interleukin (IL)-2. An in-depth analysis of this immunotherapy is provided elsewhere. In the present review, we provide an update of the most recent clinical trials with anti-CD40 antibodies. We present and discuss recent and ongoing clinical trials in this field, including clinical studies which combine anti-CD40 treatment with other cancer-treatments, such as Rituximab and Tremelimumab.Keywords
This publication has 65 references indexed in Scilit:
- Soluble CD40 ligand (sCD40L) provides a new delivery system for targeted treatmentCancer, 2012
- Costimulatory molecule expression on human uveal melanoma cells: Functional analysis of CD40 and B7-H1Experimental Eye Research, 2012
- The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cellsBlood, 2008
- Anti-CD40 agonist antibodies: Preclinical and clinical experienceUpdate on Cancer Therapeutics, 2007
- Constitutive expression of functional CD40 on mouse renal cancer cells: Induction of Fas and Fas-mediated killing by CD40LCellular Immunology, 2005
- A Role for CD40 Expression on CD8 + T Cells in the Generation of CD8 + T Cell MemoryScience, 2002
- CD40-CD40 ligandJournal of Leukocyte Biology, 2000
- Help for cytotoxic-T-cell responses is mediated by CD40 signallingNature, 1998
- The Role of the CD40 Antigen on Malignant B CellsLeukemia & Lymphoma, 1996
- Temporal association of CD40 antigen expression with discrete stages of human B-cell ontogeny and the efficacy of anti-CD40 immunotoxins against clonogenic B-lineage acute lymphoblastic leukemia as well as B- lineage non-Hodgkin's lymphoma cellsBlood, 1990